Literature DB >> 17368563

Taboo thoughts and doubt/checking: a refinement of the factor structure for obsessive-compulsive disorder symptoms.

Anthony Pinto1, Jane L Eisen, Maria C Mancebo, Benjamin D Greenberg, Robert L Stout, Steven A Rasmussen.   

Abstract

The purpose of this report was to improve upon earlier factor analyses of obsessive-compulsive disorder (OCD) symptom categories by minimizing the heterogeneity in the aggressive obsessions category. An exploratory factor analysis was conducted on data from 293 adults with primary OCD. The resulting five factors (Symmetry/Ordering, Hoarding, Doubt/Checking, Contamination/Cleaning, and Taboo Thoughts) are phenomenologically more homogeneous than prior category-based factors and are consistent with those derived in previous item-level analyses.

Entities:  

Mesh:

Year:  2007        PMID: 17368563      PMCID: PMC2039929          DOI: 10.1016/j.psychres.2006.09.005

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  18 in total

1.  The brown longitudinal obsessive compulsive study: treatments received and patient impressions of improvement.

Authors:  Maria C Mancebo; Jane L Eisen; Anthony Pinto; Benjamin D Greenberg; Ingrid R Dyck; Steven A Rasmussen
Journal:  J Clin Psychiatry       Date:  2006-11       Impact factor: 4.384

2.  [Modern typology of symptoms and obsessive-compulsive syndromes: results of a large French study of 615 patients].

Authors:  E G Hantouche; S Lancrenon
Journal:  Encephale       Date:  1996-05       Impact factor: 1.291

3.  Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.

Authors:  P Alonso; J M Menchon; J Pifarre; D Mataix-Cols; L Torres; P Salgado; J Vallejo
Journal:  J Clin Psychiatry       Date:  2001-07       Impact factor: 4.384

4.  Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial.

Authors:  David Mataix-Cols; Isaac M Marks; John H Greist; Kenneth A Kobak; Lee Baer
Journal:  Psychother Psychosom       Date:  2002 Sep-Oct       Impact factor: 17.659

5.  Further investigation of the obsessive-compulsive inventory: psychometric analysis in two non-clinical samples.

Authors:  Kevin D Wu; David Watson
Journal:  J Anxiety Disord       Date:  2003

Review 6.  Symptom subtypes of obsessive-compulsive disorder in behavioral treatment studies: a quantitative review.

Authors:  S G Ball; L Baer; M W Otto
Journal:  Behav Res Ther       Date:  1996-01

7.  Pierre Janet on obsessive-compulsive disorder (1903). Review and commentary.

Authors:  R K Pitman
Journal:  Arch Gen Psychiatry       Date:  1987-03

8.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

9.  Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders.

Authors:  L Baer
Journal:  J Clin Psychiatry       Date:  1994-03       Impact factor: 4.384

10.  The treatment of severe, chronic, resistant obsessive-compulsive disorder. An evaluation of an in-patient programme using behavioural psychotherapy in combination with other treatments.

Authors:  L M Drummond
Journal:  Br J Psychiatry       Date:  1993-08       Impact factor: 9.319

View more
  33 in total

1.  Understudied clinical dimensions in pediatric obsessive compulsive disorder.

Authors:  Adam B Lewin; Nicole Caporino; Tanya K Murphy; Gary R Geffken; Eric A Storch
Journal:  Child Psychiatry Hum Dev       Date:  2010-12

2.  Sexual orientation obsessions in obsessive-compulsive disorder: prevalence and correlates.

Authors:  Monnica T Williams; Samantha G Farris
Journal:  Psychiatry Res       Date:  2010-11-20       Impact factor: 3.222

3.  Symptom subtype and quality of life in obsessive-compulsive disorder.

Authors:  Carly M Schwartzman; Christina L Boisseau; Nicholas J Sibrava; Maria C Mancebo; Jane L Eisen; Steven A Rasmussen
Journal:  Psychiatry Res       Date:  2017-01-20       Impact factor: 3.222

4.  Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?

Authors:  Michael G Wheaton; David Rosenfield; Edna B Foa; H Blair Simpson
Journal:  J Consult Clin Psychol       Date:  2015-05-25

5.  The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder.

Authors:  Monnica T Williams; Samantha G Farris; Eric N Turkheimer; Martin E Franklin; H Blair Simpson; Michael Liebowitz; Edna B Foa
Journal:  J Anxiety Disord       Date:  2014-06-14

6.  Homosexual Obsessive Compulsive Disorder (HOCD): A Rare Case Report.

Authors:  Manjeet S Bhatia; Jaswinder Kaur
Journal:  J Clin Diagn Res       Date:  2015-01-01

Review 7.  Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective.

Authors:  David L Pauls; Amitai Abramovitch; Scott L Rauch; Daniel A Geller
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

Review 8.  Symptom dimensions in obsessive-compulsive disorder: phenomenology and treatment outcomes with exposure and ritual prevention.

Authors:  Monnica T Williams; Beth Mugno; Martin Franklin; Sonya Faber
Journal:  Psychopathology       Date:  2013-04-20       Impact factor: 1.944

9.  Altered activation in fronto-striatal circuits during sequential processing of conflict in unmedicated adults with obsessive-compulsive disorder.

Authors:  Rachel Marsh; Guillermo Horga; Nidhi Parashar; Zhishun Wang; Bradley S Peterson; H Blair Simpson
Journal:  Biol Psychiatry       Date:  2013-03-13       Impact factor: 13.382

10.  Assessing neurocognitive function in psychiatric disorders: a roadmap for enhancing consensus.

Authors:  Susanne E Ahmari; Teal Eich; Deniz Cebenoyan; Edward E Smith; H Blair Simpson
Journal:  Neurobiol Learn Mem       Date:  2014-06-30       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.